Tamara van Donge

Chapter 4 72 References 1. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. The Lancet Respiratory Medicine. 2018;6(3):223-230. 2. WHO. Pocket book of hospital care for children: guidelines for the management of common childhood illnesses. Vol 2nd edition: World Health Organization; 2013. 3. Jackson C, Hsia Y, Basmaci R, et al. Global Divergence From World Health Organization Treatment Guidelines for Neonatal and Pediatric Sepsis. The Pediatric Infectious Disease Journal. 2019. 4. Barker CI, Germovsek E, Hoare RL, Lestner JM, Lewis J, Standing JF. Pharmacokinetic/ pharmacodynamic modelling approaches in paediatric infectious diseases and immunology. Advanced drug delivery reviews. 2014;73:127-139. 5. Bijleveld YA, Mathôt RA, van der Lee JH, et al. Population pharmacokinetics of amoxicillin in term neonates undergoing moderate hypothermia. Clinical Pharmacology & Therapeutics. 2018;103(3):458-467. 6. Tang B-H, Wu Y-E, Kou C, et al. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. Antimicrobial agents and chemotherapy. 2019;63(2):e02336-02318. 7. Pullen J, Driessen M, Stolk L, et al. Amoxicillin pharmacokinetics in (preterm) infants aged 10 to 52 days: effect of postnatal age. Therapeutic drug monitoring. 2007;29(3):376-380. 8. Pullen J, Stolk LM, Nieman FH, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of amoxicillin in (pre) term neonates. Therapeutic drug monitoring. 2006;28(2):226-231. 9. Huisman-de Boer JJ, Van den Anker J, Vogel M, Goessens W, Schoemaker RC, de Groot R. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrobial agents and chemotherapy. 1995;39(2):431-434. 10. Sy SK, Zhuang L, Derendorf H. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert opinion on drug metabolism & toxicology. 2016;12(1):93-114. 11. van Donge T, Pfister M, Bielicki J, et al. Quantitative analysis of gentamicin exposure in neonates and infants calls into question its current dosing recommendations. Antimicrobial agents and chemotherapy. 2018;62(4):e02004-02017. 12. Versporten A, Bielicki J, Drapier N, et al. The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. Journal of Antimicrobial Chemotherapy. 2016;71(4):1106-1117. 13. EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. 2017. 14. Agyeman PK, Schlapbach LJ, Giannoni E, et al. Epidemiology of blood culture-proven bacterial sepsis in children in Switzerland: a population-based cohort study. The lancet child & adolescent health. 2017;1(2):124-133. 15. Ladhani SN, Henderson KL, Muller-Pebody B, Ramsay ME, Riordan A. Risk of invasive bacterial infections by week of age in infants: prospective national surveillance, England, 2010–2017. Archives of disease in childhood. 2019:archdischild-2018-316191. 16. Schrag SJ, Farley MM, Petit S, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. Pediatrics. 2016;138(6):e20162013.